Review| Volume 119, ISSUE 3, P217-224, March 2006

Smoking Increases the Treatment Failure for Helicobacter pylori Eradication



      Treatment failure for Helicobacter pylori (H. pylori) eradication is encountered in approximately 10-20% of patients, and many studies have pointed to a link with smoking. To investigate the effects of smoking on eradication outcome, we performed a meta-analysis.


      A PubMed search was performed to retrieve articles published up to August 2005. Pooled odds ratio (OR) and differences rate for H. pylori eradication failure in smokers compared with nonsmokers were used as summary statistics. Meta-regression was used for examining the source of heterogeneity.


      Twenty-two published studies (5538 patients), which provided information on eradication failure according to smoking status, were included in the analysis. The summary OR for eradication failure among smokers relative to nonsmokers was 1.95 (95% confidence interval [CI]: 1.55-2.45; P <.01). It corresponds with the differences in eradication rates between smokers and nonsmokers (8.4% [95% CI: 3.3-13.5%, P <.01]). Meta-regression analysis demonstrated that a high proportion of nonulcer dyspepsia patients in studies revealed a higher failure rate among smokers, compared with a low proportion of nonulcer dyspepsia.


      Our meta-analysis demonstrated that smoking increases the treatment failure rate for H. pylori eradication.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Marshall B.J.
        • Warren J.R.
        Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.
        Lancet. 1984; 1: 1311-1315
        • Wotherspoon A.C.
        • Ortiz-Hidalgo C.
        • Falzon M.R.
        • Isaacson P.G.
        Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma.
        Lancet. 1991; 338: 1175-1176
        • Parsonnet J.
        • Friedman G.D.
        • Vandersteen D.P.
        • et al.
        Helicobacter pylori infection and the risk of gastric carcinoma.
        N Engl J Med. 1991; 325: 1127-1131
        • Gisbert J.P.
        • Gonzalez L.
        • Calvet X.
        Systematic review and meta-analysis.
        Helicobacter. 2005; 10: 157-171
        • Graham D.Y.
        • Lew G.M.
        • Malaty H.M.
        • et al.
        Factors influencing the eradication of Helicobacter pylori with triple therapy.
        Gastroenterology. 1992; 102: 493-496
        • Lind T.
        • Megraud F.
        • Unge P.
        • et al.
        The MACH2 study.
        Gastroenterology. 1999; 116: 248-253
        • Broutet N.
        • Tchamgoue S.
        • Pereira E.
        • et al.
        Risk factors for failure of Helicobacter pylori therapy—results of an individual data analysis of 2751 patients.
        Aliment Pharmacol Ther. 2003; 17: 99-109
        • Lin C.K.
        • Hsu P.I.
        • Lai K.H.
        • et al.
        One-week quadruple therapy is an effective salvage regimen for Helicobacter pylori infection in patients after failure of standard triple therapy.
        J Clin Gastroenterol. 2002; 34: 547-551
        • van Doorn L.J.
        • Schneeberger P.M.
        • Nouhan N.
        • et al.
        Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment.
        Gut. 2000; 46: 321-326
        • Broutet N.
        • Marais A.
        • Lamouliatte H.
        • et al.
        cagA Status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia.
        J Clin Microbiol. 2001; 39: 1319-1322
        • Moayyedi P.
        • Chalmers D.M.
        • Axon A.T.
        Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori.
        J Gastroenterol. 1997; 32: 24-27
        • Kamada T.
        • Haruma K.
        • Komoto K.
        • et al.
        Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin.
        Helicobacter. 1999; 4: 204-210
        • Maconi G.
        • Parente F.
        • Russo A.
        • et al.
        Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy?.
        Am J Gastroenterol. 2001; 96: 359-366
        • Perri F.
        • Villani M.R.
        • Festa V.
        • et al.
        Predictors of failure of Helicobacter pylori eradication with the standard ‘Maastricht triple therapy’.
        Aliment Pharmacol Ther. 2001; 15: 1023-1029
        • Treiber G.
        • Wittig J.
        • Ammon S.
        • et al.
        Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication.
        Arch Intern Med. 2002; 162: 153-160
        • Lee S.B.
        • Park S.J.
        • Ryu J.K.
        • et al.
        Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
        Korean J Gastroenterol. 2003; 42: 468-475
        • De Francesco V.
        • Zullo A.
        • Hassan C.
        • et al.
        The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme.
        Dig Liver Dis. 2004; 36: 322-326
        • Janssen M.J.
        • Laheij R.J.
        • Jansen J.B.
        • de Boer W.A.
        The influence of pretreatment on cure rates of Helicobacter pylori eradication.
        Neth J Med. 2004; 62: 192-196
        • Koivisto T.T.
        • Rautelin H.I.
        • Voutilainen M.E.
        • et al.
        First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance.
        Aliment Pharmacol Ther. 2005; 21: 773-782
        • Manes G.
        • Pieramico O.
        • Perri F.
        • et al.
        Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy.
        Dig Dis Sci. 2005; 50: 443-448
        • Bertoni G.
        • Sassatelli R.
        • Nigrisoli E.
        • et al.
        Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori.
        Am J Gastroenterol. 1996; 91: 258-263
        • DerSimonian R.
        • Laird N.
        Meta-analysis in clinical trials. Prognostic role of antibody reactivity to melanoma.
        Control Clin Trials. 1986; 7: 177-188
        • Thompson S.G.
        • Sharp S.J.
        Explaining heterogeneity in meta-analysis.
        Stat Med. 1999; 18: 2693-2708
        • Begg C.B.
        • Mazumdar M.
        Operating characteristics of a rank correlation test for publication bias.
        Biometrics. 1994; 50: 1088-1101
        • Kirstein F.W.
        • Epple H.J.
        • Bojarski C.
        • et al.
        Dual versus triple therapy.
        Z Gastroenterol. 1998; 36: 803-809
        • Cutler A.F.
        • Schubert T.T.
        Patient factors affecting Helicobacter pylori eradication with triple therapy.
        Am J Gastroenterol. 1993; 88: 505-509
        • O’Connor H.J.
        • Kanduru C.
        • Bhutta A.S.
        • et al.
        Effect of Helicobacter pylori eradication on peptic ulcer healing.
        Postgrad Med J. 1995; 71: 90-93
        • Fallone C.A.
        • Barkun A.N.
        • Friedman G.
        • et al.
        Is Helicobacter pylori eradication associated with gastroesophageal reflux disease?.
        Am J Gastroenterol. 2000; 95: 914-920
        • Gisbert J.P.
        • Gonzalez L.
        • Calvet X.
        • et al.
        Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole.
        Aliment Pharmacol Ther. 2000; 14: 1319-1328
        • Kaushik S.P.
        • Vu C.
        Helicobacter pylori eradication with lansoprazole, amoxycillin and clarithromycin.
        Aust N Z J Med. 2000; 30: 231-235
        • Baena J.M.
        • Lopez C.
        • Hidalgo A.
        • et al.
        Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week.
        Eur J Gastroenterol Hepatol. 2002; 14: 291-296
        • Queiroz D.M.
        • Dani R.
        • Silva L.D.
        • et al.
        Factors associated with treatment failure of Helicobacter pylori infection in a developing country.
        J Clin Gastroenterol. 2002; 35: 315-320
        • Mantzaris G.J.
        • Petraki K.
        • Archavlis E.
        • et al.
        Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection.
        Eur J Gastroenterol Hepatol. 2002; 14: 1237-1243
        • Wu C.J.
        • Hsu P.I.
        • Lo G.H.
        • et al.
        Comparison of cetraxate-based and pantoprazole-based triple therapies in the treatment of Helicobacter pylori infection.
        J Chin Med Assoc. 2004; 67: 161-167
        • Endoh K.
        • Kauffman Jr, G.L.
        • Leung F.W.
        Mechanism of aggravation of mucosal injury by intravenous nicotine in rat stomach.
        Am J Physiol. 1991; 261: G1037-G1042
        • Holm L.
        • Perry M.A.
        Role of blood flow in gastric acid secretion.
        Am J Physiol. 1988; 254: G281-G293
        • Parente F.
        • Lazzaroni M.
        • Sangaletti O.
        • et al.
        Cigarette smoking, gastric acid secretion, and serum pepsinogen I concentrations in duodenal ulcer patients.
        Gut. 1985; 26: 1327-1332
        • Labenz J.
        • Stolte M.
        • Blum A.L.
        • et al.
        Intragastric acidity as a predictor of the success of Helicobacter pylori eradication.
        Gut. 1995; 37: 39-43
        • van der Weide J.
        • Steijns L.S.
        Cytochrome P450 enzyme system.
        Ann Clin Biochem. 1999; 36: 722-729
        • Zevin S.
        • Benowitz N.L.
        Drug interactions with tobacco smoking. An update.
        Clin Pharmacokinet. 1999; 36: 425-438
        • Villard P.H.
        • Seree E.M.
        • Re J.L.
        • et al.
        Effects of tobacco smoke on the gene expression of the Cyp1a, Cyp2b, Cyp2e, and Cyp3a subfamilies in mouse liver and lung.
        Toxicol Appl Pharmacol. 1998; 148: 195-204
        • Furuta T.
        • Ohashi K.
        • Kamata T.
        • et al.
        Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer.
        Ann Intern Med. 1998; 129: 1027-1030
        • Sagar M.
        • Tybring G.
        • Dahl M.L.
        • et al.
        Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.
        Gastroenterology. 2000; 119: 670-676
        • Degoulet P.
        • Menard J.
        • Vu H.A.
        • et al.
        Factors predictive of attendance at clinic and blood pressure control in hypertensive patients.
        Br Med J. 1983; 287 (Clin Res Ed): 88-93
        • Konturek S.J.
        • Bielanski W.
        • Plonka M.
        • et al.
        Helicobacter pylori, non-steroidal anti-inflammatory drugs and smoking in risk pattern of gastroduodenal ulcers.
        Scand J Gastroenterol. 2003; 38: 923-930
        • Hamajima N.
        • Matsuo K.
        • Saito T.
        • et al.
        Interleukin 1 polymorphisms, lifestyle factors, and Helicobacter pylori infection.
        Jpn J Cancer Res. 2001; 92: 383-389
        • Nakamura M.
        • Haruma K.
        • Kamada T.
        • et al.
        Cigarette smoking promotes atrophic gastritis in Helicobacter pylori-positive subjects.
        Dig Dis Sci. 2002; 47: 675-681
        • Endoh K.
        • Leung F.W.
        Effects of smoking and nicotine on the gastric mucosa.
        Gastroenterology. 1994; 107: 864-878
        • Matsuo K.
        • Hamajima N.
        • Ikehara Y.
        • et al.
        Smoking and polymorphisms of fucosyltransferase gene Le affect success of H. pylori eradication with lansoprazole, amoxicillin, and clarithromycin.
        Epidemiol Infect. 2003; 130: 227-233
        • Lamouliatte H.
        • Samoyeau R.
        • De Mascarel A.
        • Megraud F.
        Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia.
        Aliment Pharmacol Ther. 1999; 13: 1523-1530
        • Azuma T.
        Helicobacter pylori CagA protein variation associated with gastric cancer in Asia.
        J Gastroenterol. 2004; 39: 97-103